News & Events about Simulations Plus Inc.
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) division has released DILIsym version X (DSX) Beta, the latest version of its flagship quantitative...
Simulations Plus, Inc. (NASDAQ:SLP Get Rating) Director Walter S. Woltosz sold 20,000 shares of the firms stock in a transaction that occurred on Wednesday, December 28th. The shares were sold at an average price of $36.15, for a total transaction of $723,000.00. Following the ...
Business Wire
2 months ago
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that, through a joint proposal with the University of Baths Department of Life Sciences, it has been awarded a new funded grant from the...
Business Wire
3 months ago
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that Gustavo Mendes Lima Santos has joined its Regulatory Affairs team on a one-year fellowship appointment. Mendes Lima Santos will...
Business Wire
4 months ago
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the release of version 9.8.3 of its flagship physiologically based biopharmaceutics (PBBM) / pharmacokinetics (PBPK) modeling platform...